Parabilis Medicines initiates coverage with buy rating; price target $39
PBLS•Canaccord Genuity initiated coverage of Parabilis Medicines with a buy rating and a $39 price target.
Related News
Wall Street brokerages say AI selloff is overdone, downplay Democrat regulation risks
QQQ•
Janux Therapeutics announces positive initial Phase 1 data for JANX011 in healthy volunteers
JANX•
Biodexa provides research and development update
BDRX•
US FDA orders new eye risk warnings for Ozempic, Zepbound
LLY•
Tessera subsidiary Zorronet expands D4P Group collaboration into AI-powered EU markets
HLSQ•